Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Palonosetron: Phase III

In a double-blind North American Phase III trial in 569 patients, palonosetron met the primary endpoint of

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE